NL-OMON43934撤回不适用
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses - OPTIC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Have CP-CML and are resistant to at least two prior TKIs.
- •a.The diagnosis of CML will be made using standard hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the following:
- •i < 15% blasts in bone marrow
- •ii < 30% blasts plus promyelocytes in bone marrow
- •iii < 20% basophils in peripheral blood
- •iv * 100 × 109/L platelets (* 100,000/mm3)
- •v No evidence of extramedullary disease except hepatosplenomegaly
- •vi No prior diagnosis of AP- or BP-CML
- •b. Cytogenetic assessment at screening must demonstrate the BCR-ABL fusion by presence of the t(9;22) Philadelphia chromosome
- •i Variant translocations are only allowed provided they are assessable for cytogenetic response utilizing conventional cytogenetic techniques
- •ii Conventional chromosome banding must be performed
- •iii A minimum of 20 metaphases must be assessable at entry
- •c. Resistance to prior TKI therapy is defined as follows (patients must meet at least 1 criterion):
- •i Three months after the initiation of prior TKI therapy: No cytogenetic response (> 95% Ph+) or failure to achieve CHR or new mutation
- •ii Six months after the initiation of prior TKI therapy: BCR-ABLIS >10% and/or Ph+ >65% or new mutation
- •iii Twelve months after the initiation of prior TKI therapy: BCR-ABLIS >10% and/or Ph+ >35% or new mutation
- •iv At any time after the initiation of prior TKI therapy: The development of new BCR-ABL kinase domain mutations in the absence of CCyR or PCyR
- •v At any time after the initiation of prior TKI therapy: The development of new clonal evolution in the absence of CCyR or PCyR
- •vi At any time after the initiation of prior TKI therapy, the loss CHR, the loss of CCyR or PCyR, or confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABLIS transcript level of ><= 1% or new mutation
- •2. Be male or female patients * 18 years old.
- •3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- •4. Have adequate renal function as defined by the following criterion:
- •a. Serum creatinine * 1.5 × upper limit of normal (ULN) for institution
- •5. Have adequate hepatic function as defined by the following criteria:
- •a. Total serum bilirubin * 1.5 × ULN, unless due to Gilbert*s syndrome
- •b. Alanine aminotransferase (ALT) * 2.5 × ULN, or * 5 × ULN if leukemic infiltration of the liver is present
- •c. Aspartate aminotransferase (AST) * 2.5 × ULN, or * 5 × ULN if leukemic infiltration of the liver is present
- •6. Have normal pancreatic status as defined by the following criterion:
- •a. Serum lipase and amylase * 1.5 × ULN
- •7. Have normal QT interval corrected (Frederica) (QTcF) interval on screening electrocardiogram (ECG) evaluation, defined as QTcF of * 450 ms in males or * 470 ms in females.
- •8. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).
- •9. Agree to use a highly effective form of contraception with sexual partners from randomization through at least 4 months after the end of treatment (for female and male patients who are fertile).
- •10. Provide written informed consent.
- •11. Be willing and able to comply with scheduled visits and study procedures.
- •12. Have fully recovered (* grade 1, returned to baseline, or deemed irreversible) from the acute effects of prior cancer therapy before initiation of study drug.
排除标准
- •1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half lives of the agent, whichever is longer, prior to receiving study drug.
- •2. Received interferon or cytarabine within 14 days; immunotherapy within 14 days; or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib, or have not recovered (> grade 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], v4.0) from AEs (except alopecia) due to agents previously administered.
- •3. Have undergone autologous or allogeneic stem cell transplant (SCT) < 60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy.
- •4. Are being considered for hematopoietic SCT (HSCT) within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to HSCT in this trial).
- •5. Are taking medications with a known risk of Torsades de Pointes (APPENDIX A).
- •6. Have previously been treated with ponatinib.
- •7. Are in MCyR (defined as CCyR, PCyR, or MR2, which is * 1% BCR-ABLIS).
- •8. Have active central nervous system (CNS) disease as evidenced by cytology or pathology; in the absence of clinical CNS disease, lumbar puncture is not required. History itself of CNS involvement is not exclusionary if CNS has been cleared with a documented negative lumbar puncture.
- •9. Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- •a. Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or transient ischemic attack (TIA)
- •b. Any history of peripheral vascular infarction, including visceral infarction
- •c. Any revascularization procedure, including the placement of a stent
- •d. Congestive heart failure (CHF) (New York Heart Association [NYHA] class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment
- •e. History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia
- •f. Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment
- •10. Have uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 150 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
- •11. Have poorly controlled diabetes, defined as HbA1c values over the previous year of > 7.5% (59 mmol/mol) on more than 3 occasions. Patients with preexisting, well-controlled diabetes are not excluded.
- •12. Have a significant bleeding disorder unrelated to CML.
- •13. Have a history of alcohol abuse.
- •14. Have a history of either acute pancreatitis within 1 year of study or of chronic pancreatitis.
- •15. Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drug.
- •16. Have a history of another malignancy, other than cervical cancer in situ or basal cell or squamous cell carcinoma of the skin; the exception is if patients have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
- •17. Are pregnant or
研究者
相似试验
进行中（未招募）
1 期
Anti EGFR therapy in relapsed/refractory urothelial carcinoma.relapsed/refractory Metastatic urothelial carcinomaMedDRA version: 18.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2014-000857-35-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI120
进行中（未招募）
1 期
Placebo-controlled Trial of Pembrolizumab in Esophageal Carcinoma Participants Receiving Concurrent dCRTEsophageal CarcinomaMedDRA version: 21.0Level: LLTClassification code 10015366Term: Esophageal carcinomaSystem Organ Class: 100000004864EUCTR2019-002006-51-DKMerck Sharp & Dohme LLC600
进行中（未招募）
1 期
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)imited-Stage Small Cell Lung Cancer (LS-SCLC)MedDRA version: 21.1Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 100000004864EUCTR2019-003616-31-PTMerck Sharp & Dohme LLC672
进行中（未招募）
不适用
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Treated Indolent Non-Hodgkin LymphomaIndolent Non-Hodgkin Lymphoma (iNHL)MedDRA version: 14.1Level: HLTClassification code 10029621Term: Non-Hodgkin's lymphomas unspecified histology indolentSystem Organ Class: 100000004851EUCTR2013-003093-27-ESJanssen-Cilag International NV400
进行中（未招募）
1 期
A Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic CancerPatients with metastatic adenocarcinoma of the pancreas who have not received prior therapy for their metastatic diseaseMedDRA version: 20.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2014-004572-34-DEMerrimack Pharmaceuticals, Inc.91